Haltan-H 40 Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Hydrochlorothiazide, a thiazide diuretic, promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, further aiding in blood pressure reduction. This combination is indicated for the treatment of essential hypertension, particularly in patients who require multiple agents to achieve adequate blood pressure control. The dual mechanism of action provides complementary effects, improving antihypertensive efficacy while minimizing adverse effects associated with higher doses of individual agents. Haltan-H 40 Tablet should be administered once daily, with dosage adjustments based on clinical response and tolerability. Contraindications include hypersensitivity to either component, anuria, or severe renal impairment. Caution is advised in patients with electrolyte imbalances, hepatic dysfunction, or volume depletion. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. This medication should be used under medical supervision to optimize therapeutic outcomes and minimize risks.